At Elixir Pharma, we are proud to announce the launch of our Specialty Business Unit — a strategic expansion that marks a defining milestone in our growth journey.
This unit reflects our mission to address complex and critical health challenges by focusing on Oncology, Immunology, and Multiple Sclerosis (MS) care.

The creation of this specialized division is more than an organizational enhancement; it’s a deliberate step toward delivering advanced, high-impact therapies that meet the evolving needs of patients and healthcare providers.
By integrating specialty care into our structure, we strengthen our ability to bring meaningful innovations to those who need them most.

Among the first treatments introduced under this unit are Fumarox 120 mg, Fumarox 240 mg, and Finlim 0.5 mg — groundbreaking therapies that support the effective management of Multiple Sclerosis and significantly improve patient outcomes.
These additions represent not only scientific progress, but also our dedication to shaping a healthier future through accessible, trusted treatments.

The launch of the Specialty Business Unit strengthens our therapeutic portfolio while underscoring our long-term commitment to innovation, excellence, and patient well-being.
Together with our partners, providers, and teams, we’re determined to set a new standard in specialty care — driving progress, expanding possibilities, and advancing lives through science.